Author

Helena Sorger

Medical University of ViennaORCID 0000-0002-3380-7770Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Organism:human· 1 Organism:mouse· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Martin Lothar MetzelderiD· 2 shared Antonin MarchaisiD· 1 shared Bernadette Liegl‐AtzwangeriD· 1 shared Branka Radic-SarikasiD· 1 shared Christoph HafemeisteriD· 1 shared Corentin ThuillieziD· 1 shared Femke C. A. S. RingnaldaiD· 1 shared Florian HalbritteriD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Martin Lothar MetzelderORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A human lung organoid co-culture model of early bone sarcoma metastasis reveals contact-dependent epithelial remodeling at the metastatic interface

Martha Magdalena Zylka, Tümay Capraz, Gaël Moquin‐Beaudry, Christoph Hafemeister, Nikolina Bradaric, Lukas Watzke, Veveeyan Suresh, Ulrike M. Mann, Femke C. A. S. Ringnalda, Marco Wachtel, Matthias S. Dettmer, Corentin Thuilliez, Matthias Farlik, Helena Sorger, Antonin Marchais, , Branka Radic-Sarikas

This paper introduces a 3D co-culture model of bone sarcoma metastasis in the lung and identifies a contact-dependent epithelial remodeling response with potential therapeutic targets.

bioRxiv · Jun 8, 2026 · PreprintCancer Biology

Targeting the hyperactive STAT3/5 pathway in cutaneous T-cell lymphoma with the multi-kinase nuclear transporter inhibitor IQDMA

Saptaswa Dey, Helena Sorger, Michaela Schlederer, Isabella Perchthaler, Martin Lothar Metzelder, Lukas Kenner, Richard Moriggl, Peter Wolf

This study evaluates IQDMA, a multi-kinase inhibitor, as a targeted therapy for cutaneous T-cell lymphoma, showing significant tumor volume reduction and STAT3/5 pathway inhibition compared to PUVA.

bioRxiv · Mar 3, 2025 · PreprintCancer Biology